Loading...
•
Mar 31, 2024
Theravance Q1 2024 Earnings Report
Theravance reported a solid first quarter in 2024, driven by YUPELRI hospital sales and progress in CYPRESS execution.
Key Takeaways
Theravance Biopharma reported its first quarter 2024 financial results, highlighting a solid performance in YUPELRI hospital sales and ongoing progress with the CYPRESS study for ampreloxetine.
YUPELRI delivered a solid quarter of hospital sales execution.
The company is focused on YUPELRI growth and CYPRESS execution.
A virtual investor event is scheduled for May 23rd to discuss ampreloxetine progress.
The next milestone payment of $25.0 million will be triggered if Royalty Pharma receives $240.0 million or more in royalty payments from GSK with respect to 2024 TRELEGY global net sales.
Theravance
Theravance
Theravance Revenue by Segment
Revenue by Segment
YUPELRI Collaboration Revenue
CapyFin.com Forward Guidance
Theravance Biopharma will hold a conference call and live webcast today at 5:00 pm ET / 2:00 pm PT / 10:00 pm IST.